This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Aurora Cannabis Inc. (ACB) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) concluded the recent trading session at $6.46, signifying a -1.15% move from its prior day's close.
Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 16.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Quanterix Corporation (QTRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50% and 19.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho (QDEL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 4% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 15.63% and 3.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 131.25% and 21.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
InMode (INMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 11.11% and 2.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Q1 Earnings Match Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 33.33% and 0.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 57.14% and 8.29%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -147.06% and 4.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.